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Editorial
Addressing the commercial determinants of health begins with
clearer definition and measurement
Kelley Lee1 and Nicholas Freudenberg2

The challenge of non-communicable diseases
(NCDs) continues to grow worldwide, increasing
from 43% to 54% the global burden of disease
between 1990 and 2016 (1). In 2018, NCDs
accounted for 71% of total deaths globally, with
81% of those deaths caused by four disease types –
cardiovascular diseases, diabetes, cancers and
chronic respiratory diseases (2). By 2025, the World
Health Organization estimates, 85% of NCD
annual deaths will occur in low- and middle-income
countries (3).
The costs of treating NCDs have become
enormous in all countries. For cardiovascular
diseases alone, in the European Union, healthcare
costs totalled €110 billion in 2015 (4). Adult (>20
years) cases of diabetes worldwide have risen, from
~171 million to 463 million people between 2000
and 2019, accounting for 10% of healthcare
expenditure (5,6). Moreover, given that this
economic burden is likely to be especially heavy for
disadvantaged and marginalised people and
communities than in groups with higher
socioeconomic status across all countries (7), NCDs
are now a key driver of rising health inequities (8).
Finally, as the COVID-19 pandemic shows, high
rates of NCDs put millions of people at higher risk
of other threats to health.
Given the substantial and rising costs, as Buse
et al. note, ‘we cannot treat our way out of the NCD
epidemic (9)’. Instead, more effective prevention
strategies focused on reducing the risk factors
associated with these diseases are urgently needed
(10). A risk factor is ‘any attribute, characteristic or
exposure of an individual that increases the likelihood
of developing a disease or injury (11)’. However,

public health action to prevent NCDs has to date
primarily focused on metabolic (e.g. hypertension,
hyperlipidaemia) and modifiable behavioural risk
factors – tobacco use, harmful alcohol use, unhealthy
diets and physical inactivity (2,12). As a result, as
Horton describes, ‘progress has been inadequate and
disappointingly slow. . ..An advocacy strategy based
on four diseases and four risk factors seems
increasingly out of touch. . ..Many political leaders
believe that NCDs are just too big and too complex
a challenge. And so they are paralysed. We need a
different approach (13)’.
A profoundly different approach is the emerging
concept of the commercial determinants of health
(CDoH). It has long been recognised that NCD
prevention strategies must address the ‘circumstances
in which people are born, grow, live, work, and age,
and the systems put in place to deal with illness (14)’.
Since the late 20th century, it is arguable that the
commercial (for-profit) sector has figured most
heavily in shaping such social circumstances (15–18).
West and Marteau define CDoH as ‘factors that
influence health which stem from the profit motive
(19)’. Similarly, Kickbusch et al. write that CDoH are
‘strategies and approaches used by the private sector
to promote products and choices that are detrimental
to health (20)’. Buse et al. focus on ‘risks inherent
from consumption of, or exposure to, commercial
products – such as ultra-processed foods and
beverages, tobacco and alcohol (21)’. These
definitions contrast with recent WHO documents
that consider nongovernmental organizations,
philanthropic foundations, academic institutions
and for-profit businesses all as ‘non-state actors’ and
potential partners in NCD prevention and control
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(22), a framing that masks potential conflicts of
interest for commercial actors.
While this shift in attention to commercial factors
is welcome, current definitions offer limited
understanding of the complex pathways between
CDoH and NCDs; do not take account of the
variable and dynamic nature of CDoH over time
and space; and do not consider the potential for
positive and/or negative impacts on specific
populations. As such, the concept of CDoH has not
yet been operationalised to inform public health
action effectively (9,21). Indeed, mainstream public
health approaches remain focused on metabolic and
behavioural risk factors such as screening for
hypertension, healthy eating, smoking cessation and
improved food-labelling strategies (23). However,
interventions aimed at metabolic and behavioural
risk factors, without taking account of ‘the interrelationships of social structure, context and agency
in their impact on health and well being (24)’, have
limited impact. The CDoH concept potentially
integrates metabolic, behavioural and structural risk
factors but, to do so, clearer definition beyond a
focus on specific health-harming products and
industries, along with analytical tools to measure CDoH
as a composite of risk factors, are urgently needed.
Understanding the CDoH as a composite of risk
factors, and how these risk factors interact with
each other, is critical to the development of effective
public health interventions to prevent and control
NCDs worldwide. First, this approach shifts the
dominant emphasis in research and policy on clinical
management and behavioural change, which are
costly and limited in effect, to prevention based on
both societal- and individual-level change. Second, a
composite CDoH approach bridges research and
policy silos dividing different disease areas,
population groups and types of interventions.
Instead, these holistic approaches can amplify
change through integrated strategies for NCD
prevention. Finally, measuring the CDoH as a
composite of risk factors allows clearer identification
of relative vulnerabilities by specific populations
over time and place, and across other variables (e.g.
age, gender, socioeconomic status). This could
provide a powerful dataset to develop targeted
interventions and resources to reduce such risks to
health and health equity.
A practical interdisciplinary CDoH framework
can also incorporate new insights from systems
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science, political economy and political science,
creating new bodies of knowledge that can inform
public health practice. Systems science can help to
create more coherent and grounded understanding
of how dynamic systems of power and governance
shape the pathways through which CDoH influence
health (25). Political economy can help to trace the
impact of the rise in neoliberalism on the role of
commercial actors while political science can help to
identify the social actors who have the power to
modify CDoH (26).
Overall, despite clear evidence of the alarming rise
in NCDs globally, and high-level political
commitment to address this leading public health
challenge, the public health community (including
health promotion professionals) has achieved only
limited consensus on effective preventive action
(13,27). The CDoH concept promises a more
holistic, integrated and targeted approach.
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